Repligen Corporation

Repligen Corporation, founded in 1981 and headquartered in Waltham, Massachusetts, United States, provides advanced bioprocessing technologies to the global biopharmaceutical industry. The company drives revenue by supplying proprietary reagents, chromatography resins, and single‐use systems to major pharmaceutical firms. Under the leadership of CEO Robert E. Dutton, Repligen has secured an estimated 15-20% market share in its niche through innovative process solutions. It is focused on strategic expansion and R&D investments to fuel double-digit growth in the near term.

In December 2023 the Board authorized a stock repurchase of up to $25.0 million of common stock (the Share Repurchase Program) concurrent with issuance of the 2023 Notes; the Company did not repurchase any shares under it during the years ended December 31, 2025 and 2024 (it used $14.4 million to repurchase 92,090 shares in 2023). A separate 2008 program authorized repurchase of up to 1.25 million shares, with 657,173 shares remaining and no purchases in 2025.